Virtus ETF Advisers’s Alder Biopharmaceuticals ALDR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q4
Sell
-20,985
Closed -$396K 529
2019
Q3
$396K Sell
20,985
-1,169
-5% -$13.4K 0.08% 189
2019
Q2
$261K Buy
+22,154
New +$268K 0.06% 265
2016
Q4
Sell
-8,582
Closed -$281K 202
2016
Q3
$281K Hold
8,582
0.14% 105
2016
Q2
$214K Buy
8,582
+1,309
+18% +$35.4K 0.16% 130
2016
Q1
$178K Sell
7,273
-455
-6% -$10.5K 0.25% 101
2015
Q4
$255K Buy
+7,728
New +$261K 0.7% 63

Virtus ETF Advisers's ALDR Position: Q4 2019 in Review

Virtus ETF Advisers sold out of Alder Biopharmaceuticals (ALDR) in Q4 2019, closing a stake of 20,985 shares — an estimated $396K sold.

Virtus ETF Advisers first reported a position in ALDR in Q4 2015 and held it in 6 quarters. The position peaked at $396K in Q3 2019. 0 funds tracked by Wall St. Rank hold ALDR as of Q4 2019.

  • Virtus ETF Advisers reported no remaining Alder Biopharmaceuticals position as of Q4 2019 after selling out during the quarter.
  • Virtus ETF Advisers sold 20,985 Alder Biopharmaceuticals shares in Q4 2019, an estimated $396K.
  • Virtus ETF Advisers first reported a position in Alder Biopharmaceuticals in Q4 2015 and held it in 6 quarters.
  • Virtus ETF Advisers's Alder Biopharmaceuticals position peaked at $396K in Q3 2019.
  • 0 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q4 2019.

Based on Virtus ETF Advisers's 13F filing for Q4 2019, filed 13 Feb 2020.